The Evolving Field of Biomarker Testing in Solid Tumors

A panel of experts discusses molecular testing and the use of targeted agents in lung and breast cancers, including best practices for ordering testing and how to factor results into treatment decisions.

EP. 1: Available Molecular Tests for Solid Tumors

August 29th 2022

Andrew McKenzie, PhD, provides an overview of the various forms of molecular testing available for identifying actionable alterations in breast and lung cancer.

EP. 2: Using Molecular Testing to Guide Treatment Decisions

August 29th 2022

Gregory Vidal, MD, PhD, highlights the benefits and drawbacks of the available biomarker testing options and how the results guide treatment decision-making.

EP. 3: PD-L1 Expression and IO Therapy in Lung and Breast Cancer

September 3rd 2022

A conversation on PD-L1 biomarker expression in lung cancer, and how it influences treatment with immunotherapy and chemotherapy.

EP. 4: Clinical Scenario: A 44-Year-Woman with Metastatic Breast Cancer

September 3rd 2022

Dr Martin Dietrich presents a second clinical scenario of a 44-year-old woman with metastatic, highly-aggressive breast cancer.

EP. 5: Currently Targetable Mutations in Lung and Breast Cancer

September 6th 2022

Drs Dietrich and Vidal discuss the currently known targetable actionable mutations in breast cancer and lung cancer.

EP. 6: Choosing a Molecular Testing Panel for Solid Tumors

September 6th 2022

Dr Andrew McKenzie explains how to choose the appropriate molecular testing for a patient.

EP. 7: Biomarker Testing Interpretation in Breast and Lung Cancer

September 12th 2022

Andrew McKenzie, PhD, details how to interpret the results of biomarker testing in breast cancer and lung cancer.

EP. 8: Challenges of Biomarker Testing in Breast Cancer

September 12th 2022

Dr Gregory Vidal describes the approaches for biomarker testing in breast cancer and the challenges clinicians face.

EP. 9: Use of Liquid Biopsies in Breast Cancer

September 20th 2022

Drs McKenzie and Vidal debate the use of liquid biopsies in breast cancer.

EP. 10: Discussing Biomarker Testing with Patients

September 20th 2022

Ellen Ball, ANP-FNP, provides a look at the conversations she has with patients when discussing their options for genetic testing in breast cancer.

EP. 11: Biomarker-Influenced Treatment Approaches for Patients with Metastatic Lung Cancer

September 26th 2022

Martin Dietrich, MD, PhD, explains the rationale for the chosen treatment approach in the presented clinical scenario of metastatic lung cancer.

EP. 12: Clinical Scenario: A 74-Year-Old Man with Lung Cancer

September 26th 2022

A panel of experts discusses the clinical scenario of a 74-year-old man with metastatic lung cancer and the best genetic testing approach.

EP. 13: Further Molecular Testing in Early-Stage Metastatic Breast Cancer

October 10th 2022

Gregory Vidal, MD, PhD, discusses the potential use of further molecular testing in early-stage first-line breast cancer.

EP. 14: Targeted Therapy in Metastatic Breast Cancer for Patients with BRCA Mutations

October 10th 2022

Key opinion leaders explain how early they introduce targeted therapy in mutated breast cancer.

EP. 15: Monitoring Patients on First-Line Treatment for Metastatic Breast Cancer

October 17th 2022

Ellen Ball, ANP-FNP, reviews how patients are monitored for treatment response and toxicities during first-line treatment.

EP. 16: Biomarker Testing Standards-of-Care in Breast and Lung Cancer

October 17th 2022

The panel shares their recommendations for biomarker testing standard-of-care in breast cancer and lung cancer.